Skip to content

Veracyte VCYT Net Investment in Lease

Net Investment in Lease at other companies

Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY
Quest Diagnostics logo
Quest DiagnosticsDGX
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's net investment in lease?
Veracyte (VCYT) reported net investment in lease of $35.87M in Q1 2026.
How has Veracyte's net investment in lease changed year-over-year?
Veracyte's net investment in lease decreased by 24.7% year-over-year, from $47.62M to $35.87M.
What is the long-term trend for Veracyte's net investment in lease?
Over 5 years (2020 to 2025), Veracyte's net investment in lease has grown at a 36.1% compound annual growth rate (CAGR), from $7.84M to $36.6M.